A Multiple Dose, Placebo-Controlled Trial to Determine the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of ALD403, a Humanized Anti-(Calcitonin Gene-Related Peptide) Monoclonal Antibody in Healthy Volunteers

Trial Profile

A Multiple Dose, Placebo-Controlled Trial to Determine the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of ALD403, a Humanized Anti-(Calcitonin Gene-Related Peptide) Monoclonal Antibody in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs Eptinezumab (Primary) ; Eptinezumab (Primary) ; Eptinezumab (Primary)
  • Indications Migraine
  • Focus Adverse reactions
  • Sponsors Alder Biopharmaceuticals
  • Most Recent Events

    • 15 Sep 2016 According to an Alder Biopharmaceuticals media release, results from this trial presented at the 5th European Headache and Migraine Trust International Congress (EHMTIC 2016).
    • 15 Sep 2016 Results published in an Alder Biopharmaceuticals Media Release
    • 08 Sep 2016 According to an Alder Biopharmaceuticals media release, results from this trial will be presented at the 5th European Headache and Migraine Trust International Congress (EHMTIC 2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top